Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Seema A Bhat, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Nyla A Heerema, PhD, Lynne V. Abruzzo, MD PhD, Cecelia Miller, PhD, Jennifer Zvosec, CCRP, Kasturi Ganesh-Barki, MBBS, John C. Byrd, MD, Jennifer A. Woyach, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-138612

Published: 2020

Journal Articles

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Daniel Goldstein, MD, Kyle A. Beckwith, MDPhD, Cecelia Miller, PhD, Ying Huang, MS, MA, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, David A. Bond, MD, John C. Byrd, MD, Michael R. Grever, MD, Nyla A Heerema, PhD, Kerry A. Rogers, MD, Amy S. Ruppert, PhD, Jennifer A. Woyach, MD, Adam S. Kittai, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136714

Published: 2020

Journal Articles

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, Corinne Hoffman, MS, CNP, Kami J. Maddocks, MD, Gerard Lozanski, MD, Adam S. Kittai, MD, Mollie E. Moran, Mark Reid, CNP, Jennifer A. Woyach, MD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-137655

Published: 2020

Journal Articles

Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy

Leylah Azali, PharmD, Lindsay Hazelden, PharmD, Tracy Wiczer, PharmD, Marilly Palettas, Rebekah Thomas, Connor Aossey, James S. Blachly, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Kerry A. Rogers, MD, John C. Byrd, MD, Jennifer A. Woyach, MD, Daniel Addison, MD, Seema A Bhat, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137800

Published: 2020

Journal Articles

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Jennifer A. Woyach, MD, James S. Blachly, MD, Kerry A. Rogers, MD, Seema A Bhat, MD, Michael R. Grever, MD, Adam S. Kittai, MD, Mojgan Jianfar, MD, Gerard Lozanski, MD, David M. Weiss, Barbara L. Andersen, PhD, Priti Patel, MD, Veerendra Munugalavadla, PhD, Anna Butturini, MD, Yan Xu, Min Hui Wang, PhD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-136317

Published: 2020

Journal Articles

Phase Ib Study of Ianalumab (VAY736) and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy

Kerry A. Rogers, MD, Ian W. Flinn, MD PhD, Carolyn McGarry, PhD, Liangke Connie Gou, PhD, Nadia Hassounah, PhD, Janghee Woo, MD, John C. Byrd, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-137629

Published: 2020

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Kerry A. Rogers, MD, Michael A. Boxer, MD, Michael Y. Choi, MD, Richy Agajanian, MD, Donald M. Arnold, MD, Catherine M. Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Donna Chow, Robert P. Numerof, PhD, Hanzhe Zheng, PhD, Sandy Tong, MD, David J. Kuter

Blood (2019) 134 (Supplement_1): 3518.

https://doi.org/10.1182/blood-2019-126509

Published: 2019

Journal Articles

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Kristin Koenig, MD, Emily Dotson, PharmD, Shane Sheredy, Seema A. Bhat, MD, John C. Byrd, MD, Tracy Wiczer, Jennifer Woyach, MD, Farrukh T. Awan, MD, Kerry A. Rogers, MD

Blood (2019) 134 (Supplement_1): 3045.

https://doi.org/10.1182/blood-2019-124538

Published: 2019

Journal Articles

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Kerry A Rogers, MD, Lai Wei, PhD, Seema A. Bhat, MD, Dan Jones, MD PhD, Erlene K. Seymour, MD, Deborah M. Stephens, DO, J Christine Ye, MDMSc, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 3049.

https://doi.org/10.1182/blood-2019-125360

Published: 2019

Journal Articles

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Meixiao Long, MD, Erich Williams, Clara Berard, Carolyn Cheney, BS, Eileen Hu, BS, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1049.

https://doi.org/10.1182/blood-2019-125417

Published: 2019

Journal Articles

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

Ashley E. Rosko, MD, Sarah A Wall, MD, Robert A Baiocchi, MD PhD, Don M. Benson, Jr., MD PhD, Jonathan E. Brammer, MD, John C. Byrd, MD, Yvonne A. Efebera, MD MPH, Kami J. Maddocks, MD, Kerry A. Rogers, MD, Carolyn Presley, MD, Desiree Jones, Ying Huang, MS, MA, Michelle Naughton, PhD MPH

Blood (2019) 134 (Supplement_1): 4776.

https://doi.org/10.1182/blood-2019-130531

Published: 2019

Journal Articles

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

Deborah M. Stephens, DO, Ying Huang, MS, MA, Akwasi Agyeman, Amy S. Ruppert, MAS, PhD, Boyu Hu, MD, Natalie Turner, APRN, Renee Vadeboncoeur, MSN, APRN, Kerry A Rogers, MD, Seema A. Bhat, MD, Basem M. William, MRCP,MD, Samantha Jaglowski, MDMPH, Hank Lockman, Martha Glenn, MD, Rosa Lapalombella, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 4310.

https://doi.org/10.1182/blood-2019-124544

Published: 2019

Journal Articles

LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia

Eileen Hu, BS, Hatice Gulcin Ozer, PhD, Arletta Lozanski, Tzyy-Jye Doong, Chi-Ling Chiang, PhD, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, James S. Blachly, MD, Gerard Lozanski, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 3377.

https://doi.org/10.1182/blood-2019-126070

Published: 2019

Journal Articles

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study

David J. Kuter, MD DPhil, Richy Agajanian, MD, Donald M. Arnold, MD MSc, FRCPC, Michael Boxer, MD, Catherine Broome, MD, Joshua J. Field, MD, Irina Murakhovskaya, MD, Kerry A. Rogers, MD, Ann M Lowe, MD, Sandra Tong, MD, Hany Zayed, PhD, Anne-Marie Duliege, MD MS

Blood (2018) 132 (Supplement 1): 3612.

https://doi.org/10.1182/blood-2018-99-110483

Published: 2018

Journal Articles

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Blood (2018) 132 (Supplement 1): 6.

https://doi.org/10.1182/blood-2018-99-116653

Published: 2018

Journal Articles

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MA, MS, Amy S. Ruppert, MAS, PhD, Farrukh T. Awan, MD MS, Corrinne Hoffman, CNP, Kami J. Maddocks, MD, Mark Reid, CNP, Jennifer A. Woyach, MD, Thomas Whitlow, BA, Jeffrey A. Jones, MD MPH, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 693.

https://doi.org/10.1182/blood-2018-99-114169

Published: 2018

Journal Articles

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies

Tyler Dickerson, PharmD, Tracy Wiczer, Allyson Waller, Jennifer Philippon, Devin Haddad, Avirup Guha, Kyle Porter, Kerry A. Rogers, MD, Jennifer A. Woyach, MD, John C. Byrd, MD, Daniel Addison, Farrukh T. Awan, MD MS

Blood (2018) 132 (Supplement 1): 4423.

https://doi.org/10.1182/blood-2018-99-110345

Published: 2018

Journal Articles

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Mirela Anghelina, Narendranath Epperla, MD MS, Kerry A. Rogers, MD, Ling Guo, MD, Qiuhong Zhao, MS, James S. Blachly, MD, David M. Lucas, PhD, Christopher C. Oakes, Gerard Lozanski, MD, Michael R. Grever, MD, Leslie A. Andritsos, MD

Blood (2018) 132 (Supplement 1): 4143.

https://doi.org/10.1182/blood-2018-99-120043

Published: 2018

Journal Articles

Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment

Narendranath Epperla, MDMS, Mirela Anghelina, Qiuhong Zhao, MS, Akwasi Agyeman, James S. Blachly, MD, Kerry A. Rogers, MD, Gerard Lozanski, MD, Christopher C. Oakes, Michael R. Grever, MD, Leslie Andritsos, MD

Blood (2018) 132 (Supplement 1): 2305.

https://doi.org/10.1182/blood-2018-99-119951

Published: 2018

Journal Articles

Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment

Elizabeth Kander, MD, Qiuhong Zhao, MS, Tracy Wiczer, John C. Byrd, MD, Jennifer A. Woyach, MD, Farrukh T. Awan, MD MS, Kerry A. Rogers, MD, Tzu-Fei Wang, MD

Blood (2018) 132 (Supplement 1): 3148.

https://doi.org/10.1182/blood-2018-99-110556

Published: 2018

NARROW

Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy

Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase Ib Study of Ianalumab (VAY736) and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy

Fostamatinib, a Spleen Tyrosine Kinase (SYK) Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): Final Results of the Phase 2, Multicenter, Open-Label Study

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Restoring Functional Deficits in Older Adults with Hematologic Malignancy

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

LC-Facseq: A Novel Method for Detecting Rare Resistant Clones in Leukemia

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia: Initial Results of the Multicenter, Open-Label Extension Period of the Soar Phase 2 Study

Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202

Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia

Hypertension Development, Management, and Cardiovascular Events Following Ibrutinib Initiation for Hematologic Malignancies

Down-Regulation of CD25 Antigen in Hairy Cell Leukemia Patients after Treatment

Infection at the Time of Initial Therapy for Hairy Cell Leukemia Is Associated with Inferior Time to Next Treatment

Incidence, Type, and Management of Venous and Arterial Thrombosis during Ibrutinib Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only